基石药业-B (02616.HK) 于7月23日发布重要动态。公司宣布，其董事及高级管理层已于2026年6月期间，在公开市场购入总计240万股公司股份。此举彰显了管理层对公司未来发展的坚定信心与长期承诺。
与此同时，公司披露了其核心在研产品CS2009的研发进展。基石药业计划于2026年底前，正式启动针对CS2009的全球多中心三期临床试验（MRCTS）。这一关键步骤标志着该药物研发进入决定性阶段，其全球开发计划正稳步推进。
管理层的增持行为与核心产品研发进入关键阶段的消息相继发布，向市场传递了积极信号。投资者通常将此类内部人士购入股份视为对公司价值认可的重要指标，结合CS2009的研发里程碑，共同勾勒出公司未来的成长路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.